Original Research
Published on 28 Oct 2022
Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
in Drugs Outcomes Research and Policies

- 3,232 views
- 12 citations
Original Research
Published on 28 Oct 2022
in Drugs Outcomes Research and Policies
Systematic Review
Published on 28 Oct 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 26 Oct 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 26 Oct 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 26 Oct 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 25 Oct 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 24 Oct 2022
in Drugs Outcomes Research and Policies
Systematic Review
Published on 24 Oct 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 21 Oct 2022
in Drugs Outcomes Research and Policies
Systematic Review
Published on 20 Oct 2022
in Drugs Outcomes Research and Policies
Brief Research Report
Published on 20 Oct 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 19 Oct 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 18 Oct 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 17 Oct 2022
in Drugs Outcomes Research and Policies
Original Research
Published on 17 Oct 2022
in Drugs Outcomes Research and Policies
Review
Published on 14 Oct 2022
in Drugs Outcomes Research and Policies